华森制药(002907) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥164,915,909.05, representing a 30.90% increase compared to ¥125,987,356.97 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2018 was ¥29,449,190.31, up 36.09% from ¥21,639,357.38 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥26,364,609.16, a 23.57% increase from ¥21,335,980.15 year-on-year[8]. - The basic earnings per share for Q1 2018 was ¥0.0736, reflecting a 22.46% increase from ¥0.0601 in the same quarter last year[8]. - The company's operating revenue for the reporting period was $164.92 million, an increase of 30.90% compared to the previous period, driven by expanded production scale and increased sales channels[16]. - The company reported a net profit attributable to shareholders for the first half of 2018 expected to be between $4.80 million and $7.00 million, representing a growth range of 4.08% to 51.78% compared to the same period in 2017[19]. Assets and Shareholder Information - The total assets at the end of the reporting period were ¥911,100,028.85, a 2.93% increase from ¥885,147,684.26 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were ¥749,395,689.23, up 4.09% from ¥719,946,498.92 at the end of the previous year[8]. - The total number of ordinary shareholders at the end of the reporting period was 38,504[12]. - The largest shareholder, Chengdu Local Construction Machinery Engineering Co., Ltd., held 47.02% of the shares, totaling 188,100,000 shares[12]. Cash Flow and Expenses - The net cash flow from operating activities was ¥3,162,671.12, a significant decrease of 89.34% compared to ¥29,679,968.22 in the same period last year[8]. - Sales expenses increased by 37.13% to $65.45 million, attributed to higher costs related to wages, social security, travel, and marketing[16]. - The company’s cash outflow for tax payments rose by 58.64% to $27.61 million, reflecting increased sales revenue[17]. Government Support and Other Income - The company received government subsidies amounting to ¥250,000 during the reporting period[9]. - The company received government subsidies and tender deposits amounting to $6.88 million, a 303.21% increase from the previous period[16]. - Other income increased significantly by 469.51% to $2.03 million, primarily due to financial support from the Chongqing municipal government[16]. Investments and Borrowings - Accounts receivable increased by 55.30% to $692,230.14 due to the purchase of bank principal-protected financial products, resulting in higher investment income[16]. - The company recorded an investment income of $1.35 million from bank financial products, marking a 100% increase[16]. - Short-term borrowings were fully repaid, resulting in a 100% decrease from $17 million at the beginning of the period[16]. - Long-term deferred expenses decreased by 36.17% to $175,613.73 due to normal amortization during the reporting period[16].